Ratings AVITA Medical, Inc. Australian S.E.

Equities

AVH

AU000000AVH4

Delayed Australian S.E. Other stock markets 10:51:52 30/04/2024 am IST			5-day change	1st Jan Change
2.66 ^AUD	-1.48%		-1.12%	-38.00%

17/04	Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03	MT
11/04	BTIG Research Downgrades Avita Medical to Neutral From Buy	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AVITA MEDICAL, INC.	-38.00%	225M	C
IQVIA HOLDINGS INC.	+1.77%	42.86B	B
LONZA GROUP AG	+47.70%	41.36B	A
MODERNA, INC.	+12.24%	42.74B	B-
CELLTRION, INC.	-8.83%	27.68B	C
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B	B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B	C+
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders